Drug Insight: antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease

被引：0
|
作者：
John T Chang
Gary R Lichtenstein
机构：
[1] Center for Inflammatory Bowel Diseases,Fellow in Gastroenterology Division of Gastroenterology
[2] Hospital of the University of Pennsylvania,Professor of Medicine and Director of the Division of Gastroenterology
[3] Center for Inflammatory Bowel Diseases,undefined
[4] Hospital of the University of Pennsylvania,undefined
来源：
Nature Clinical Practice Gastroenterology & Hepatology | 2006年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Advances in the understanding of the pathogenesis of inflammatory bowel disease have allowed rational therapeutic targets to be developed, including antagonists of tumor-necrosis factor-α. The authors of this Review provide insights into the similarities and differences of the mechanism of action, clinical efficacy and limitations of the tumor-necrosis factor-α antagonists infliximab, adalimumab, certolizumab, CDP571, etanercept, and onercept.
引用
收藏
页码：220 / 228
页数：8
相关论文
共 50 条
  • [1] Drug insight:: Antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease
    Chang, JT
    Lichtenstein, GR
    [J]. NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2006, 3 (04): : 220 - 228
  • [2] Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease
    Ordas, Ingrid
    Feagan, Brian G.
    Sandborn, William J.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2012, 10 (10) : 1079 - 1087
  • [3] Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update
    Leso, Veruscka
    Leggio, Lorenzo
    Armuzzi, Alessandro
    Gasbarrini, Giovanni
    Gasbarrini, Antonio
    Addolorato, Giovanni
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (07) : 779 - 786
  • [4] Optimizing Therapeutic Drug Monitoring of Tumor Necrosis Factor-α Antagonists in Patients With Inflammatory Bowel Diseases
    Cui, Dejun
    Hu, Mei
    Zhao, Xun
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (10) : 1509 - 1509
  • [5] Effect of Tumor Necrosis Factor-α Inhibitors on Drug-Induced Pancreatitis in Inflammatory Bowel Disease
    Stobaugh, Derrick J.
    Deepak, Parakkal
    [J]. ANNALS OF PHARMACOTHERAPY, 2014, 48 (10) : 1282 - 1287
  • [6] Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease
    Gareb, Bahez
    Otten, Antonius T.
    Frijlink, Henderik W.
    Dijkstra, Gerard
    Kosterink, Jos G. W.
    [J]. PHARMACEUTICS, 2020, 12 (06) : 1 - 31
  • [7] Tumor Necrosis Factor-α Monoclonal Antibodies in the Treatment of Inflammatory Bowel Disease: Clinical Practice Pharmacology
    Lee, Thomas W.
    Fedorak, Richard N.
    [J]. GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2010, 39 (03) : 543 - +
  • [8] Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases
    Siddharth Singh
    Herbert C. Heien
    Lindsey Sangaralingham
    Nilay D. Shah
    William J. Sandborn
    [J]. Digestive Diseases and Sciences, 2022, 67 : 2510 - 2516
  • [9] Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases
    Singh, Siddharth
    Heien, Herbert C.
    Sangaralingham, Lindsey
    Shah, Nilay D.
    Sandborn, William J.
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (06) : 2510 - 2516
  • [10] Targeting tumor necrosis factor-α in inflammatory bowel disease:: why, how, and when?
    Hommes, DW
    van Deventer, SJH
    [J]. CURRENT OPINION IN GASTROENTEROLOGY, 2003, 19 (04) : 350 - 357
12345